临床荟萃 ›› 2021, Vol. 36 ›› Issue (9): 782-785.doi: 10.3969/j.issn.1004-583X.2021.09.003

• 论著 • 上一篇    下一篇

沙库巴曲缬沙坦钠联合新活素治疗急性左心衰竭的疗效

罗方林(), 官素英, 吴国祥   

  1. 福建医科大学附属南平市第一医院 心内一区,福建 南平 353000
  • 收稿日期:2021-06-02 出版日期:2021-09-20 发布日期:2021-10-05
  • 通讯作者: 罗方林 E-mail:bobby_mailbox@163.com

Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure

Luo Fanglin(), Guan Suying, Wu Guoxiang   

  1. Department of Cardiology, the First Affiliated Hospital of Nanping, Fujian Medical University, Nanping 353000, China
  • Received:2021-06-02 Online:2021-09-20 Published:2021-10-05
  • Contact: Luo Fanglin E-mail:bobby_mailbox@163.com

摘要:

目的 探讨沙库巴曲缬沙坦钠联合新活素(冻干重组人脑利钠肽)治疗急性左心衰竭( ALHF)的疗效。方法 选择本院2018年6月-2020年10月收诊的ALHF患者112例,随机数字表法分为试验组(56例,沙库巴曲缬沙坦钠联合新活素)与对照组(56例,沙库巴曲缬沙坦钠)2组,观察两组用药2周后的总有效率,分析其心率、血浆N末端B型利钠肽前体(NT-proBNP)、左心室射血分数(LVEF)水平,以及比较其丙二醛(MDA) 、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平。结果 实验组的总有效率高于对照组(92.86% vs 76.79%,P<0.05)。实验组用药后的心率、NT-proBNP、MDA低于对照组(P<0.05);而其LVEF、SOD、GSH-Px高于对照组(P<0.05)。结论 沙库巴曲缬沙坦钠联合新活素方法有助于改善ALHF患者的心功能,减轻其氧化应激,稳定提升其临床疗效。

关键词: 心力衰竭, 氧化性应激, 药物疗法, 联合

Abstract:

Objective To investigate the clinical effect of sacubitril-valsartan combined with recombinant human brain natriuretic peptide for acute left heart failure(ALHF). Methods A total of 112 ALHF patients admitted to our hospital from June 2018 to October 2020 were by random number table method divided into experimental group (56 cases received sacubitril-valsartan combined with activin) and control group (56 cases received sacubitril-valsartan). After treatment, the total effective rate, heart rate, N-terminal pro-brain natriuretic peptide(NT-proBNP) and left ventricular ejection fraction(LVEF) were analyzed. Malondialdehyde(MDA), superoxide dismutase(SOD) and glutathione peroxidase(GSH-Px) were compared in two groups. Results The total effective rate in experimental group was higher than that of control group (92.86% vs 76.79%, P<0.05). After treatment, the heart rate, NT-proBNP and MDA were lower in experimental group than in control group (P<0.05), while LVEF, SOD and GSH-Px were higher than in control group (P<0.05). Conclusion Sacubitril-valsartan combined with activin can improve cardiac function for ALHF patients, reduce oxidative stress, and stably enhance clinical efficacy.

Key words: heart failure, oxidative stress, drug therapy

中图分类号: